Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7732430 | MAYNE PHARMA | Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception |
Mar, 2025
(11 months from now) | |
US11793760 | MAYNE PHARMA | Orodispersible dosage unit containing an estetrol component |
Jun, 2036
(12 years from now) |
Nextstellis is owned by Mayne Pharma.
Nextstellis contains Drospirenone; Estetrol.
Nextstellis has a total of 2 drug patents out of which 0 drug patents have expired.
Nextstellis was authorised for market use on 15 April, 2021.
Nextstellis is available in tablet;oral dosage forms.
Nextstellis can be used as use by females of reproductive potential to prevent pregnancy.
Drug patent challenges can be filed against Nextstellis from 2025-04-15.
The generics of Nextstellis are possible to be released after 17 June, 2036.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 15, 2026 |
Drugs and Companies using DROSPIRENONE; ESTETROL ingredient
NCE-1 date: 2025-04-15
Market Authorisation Date: 15 April, 2021
Treatment: Use by females of reproductive potential to prevent pregnancy
Dosage: TABLET;ORAL